{"id":200,"date":"2020-06-03T15:47:38","date_gmt":"2020-06-03T13:47:38","guid":{"rendered":"https:\/\/semmelweis.hu\/gyermekklinika1\/?page_id=200"},"modified":"2024-11-27T12:48:15","modified_gmt":"2024-11-27T11:48:15","slug":"mta-se-lendulet-diabetesz-kutatocsoport","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/bokayklinika\/kutatas\/mta-se-lendulet-diabetesz-kutatocsoport\/","title":{"rendered":"MTA-SE LEND\u00dcLET Diab\u00e9tesz Kutat\u00f3csoport"},"content":{"rendered":"
Vezet\u0151:<\/strong> Prof. Dr. Fekete Andrea<\/div>\n

A t\u00f6bb mint k\u00e9t \u00e9vtizedes alapkutat\u00f3i \u00e9s klinikai farmakol\u00f3giai m\u00faltj\u00e1val rendelkez\u0151 MTA-SE Lend\u00fclet Diab\u00e9tesz Kutat\u00f3csoport els\u0151dleges c\u00e9lja, hogy laborat\u00f3riumi felfedez\u00e9seit klinikai gyakorlatba \u00fcltesse. Kutat\u00e1saink a cukorbetegs\u00e9g olyan sz\u00f6veti hegesed\u00e9ssel j\u00e1r\u00f3 sz\u00f6v\u0151dm\u00e9nyeire f\u00f3kusz\u00e1lnak, mint a diab\u00e9teszes vesebetegs\u00e9g, valamint a glauk\u00f3ma.<\/p>\n

A cukorbetegs\u00e9g t\u00f6bb mint 500 milli\u00f3 embert \u00e9rint vil\u00e1gszerte, a betegs\u00e9g prevalenci\u00e1ja folyamatosan n\u0151, tov\u00e1bb\u00e1 szignifik\u00e1nsan cs\u00f6kkenti a v\u00e1rhat\u00f3 \u00e9lettartamot. Sz\u00e1mos sz\u00f6v\u0151dm\u00e9nye k\u00f6z\u00fcl kiemelend\u0151 a diab\u00e9teszes vesebetegs\u00e9g, amely a kr\u00f3nikus vesek\u00e1rosod\u00e1s vezet\u0151 oka. A cukorbetegs\u00e9g emellett nagym\u00e9rt\u00e9kben n\u00f6veli az els\u0151dleges nyitott zug\u00fa glauk\u00f3ma kialakul\u00e1s\u00e1nak es\u00e9ly\u00e9t, amely a vaks\u00e1g vezet\u0151 okak\u00e9nt k\u00f6zel 70 milli\u00f3 embert \u00e9rint.<\/p>\n

A cukorbetegs\u00e9ghez kapcsolhat\u00f3 betegs\u00e9gek mellett nagy hangs\u00falyt helyez\u00fcnk a pulmon\u00e1ris fibr\u00f3zis pathomechanizmus\u00e1nak felder\u00edt\u00e9s\u00e9re, valamint hat\u00e9kony ter\u00e1pia fejleszt\u00e9s\u00e9re. A t\u00fcd\u0151fibr\u00f3zis igen rossz progn\u00f3zis\u00fa betegs\u00e9g, mely sor\u00e1n a sz\u00f6veti hegesed\u00e9s s\u00falyos funkci\u00f3roml\u00e1shoz, valamint l\u00e9gz\u00e9si el\u00e9gtelens\u00e9ghez vezet.<\/p>\n

Ezen betegs\u00e9gekre jelenleg nincs hat\u00e9kony ter\u00e1pia, ez\u00e9rt munk\u00e1nk sor\u00e1n \u00faj gy\u00f3gyszer c\u00e9lpontokat azonos\u00edtunk \u00e9s innovat\u00edv gy\u00f3gym\u00f3dokat fejleszt\u00fcnk. A kutat\u00e1sunk f\u00f3kusz\u00e1ban \u00e1ll\u00f3 Sigma-1 receptor agonist\u00e1k \u00faj ter\u00e1pi\u00e1s megk\u00f6zel\u00edt\u00e9st ny\u00fajthatnak a kr\u00f3nikus sz\u00f6veti hegesed\u00e9ssel j\u00e1r\u00f3 betegs\u00e9gek kezel\u00e9s\u00e9re.<\/p>\n

K\u00fcl\u00f6nb\u00f6z\u0151 \u00e1llat- \u00e9s<\/em> in vitro <\/em>modelleken v\u00e9gzett k\u00eds\u00e9rleteinkben a legmodernebb molekul\u00e1ris biol\u00f3giai- \u00e9s k\u00e9palkot\u00f3 m\u00f3dszereket alkalmazzuk, melyek hozz\u00e1j\u00e1rulnak a betegs\u00e9gek patomechanizmusa m\u00f6g\u00f6tt h\u00faz\u00f3d\u00f3 biol\u00f3giai folyamatok m\u00e9lyebb meg\u00e9rt\u00e9s\u00e9hez.<\/p>\n

Csoportunk jelenleg \u00f6t posztdoktorb\u00f3l, illetve \u00f6t PhD hallgat\u00f3b\u00f3l \u00e1ll, emellett t\u00f6bb TDK hallgat\u00f3 seg\u00edti munk\u00e1nkat. Kutat\u00e1saink anyagi t\u00e1mogat\u00e1s\u00e1t t\u00f6bbek k\u00f6z\u00f6tt a Lend\u00fclet program, valamint a Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal tudom\u00e1nyos p\u00e1ly\u00e1zatai biztos\u00edtj\u00e1k.<\/p>\n

\n
MTA-SE, Lend\u00fclet Diabetes Research Group<\/strong>
\nSupervisor:<\/strong> Prof. Andrea Fekete, MD, DSc<\/div>\n

With over two decades of expertise in basic science and clinical pharmacology, the MTA-SE Lend\u00fclet „Momentum” Diabetes Research Group is at the forefront of translating laboratory discoveries into clinical therapies. Our primary mission is to address the complexities of diabetes and its complications, focusing mainly on diabetic kidney disease and diabetic eye disorders\u2014all characterized by pathological tissue remodeling.<\/p>\n

Diabetes poses a significant global health challenge, affecting over 500 million individuals worldwide. The prevalence of diabetes is rising rapidly, and the disease is a major contributor to reduced life expectancy, typically shortening it by 5 to 10 years. Among its many complications, diabetic kidney disease stands as the leading cause of chronic kidney disease, which affects more than 840 million people globally. Additionally, diabetes significantly increases the risk of primary open-angle glaucoma, a leading cause of blindness affecting nearly 70 million people.<\/p>\n

In addition to diseases related to diabetes, we place great emphasis on uncovering the pathomechanism of pulmonary fibrosis and developing effective therapies. Pulmonary fibrosis has a very poor prognosis, during which tissue scarring leads to severe functional impairment and ultimately respiratory failure.<\/p>\n

There are currently no effective therapies for these diseases; thus, in our work, we aim to identify new drug targets and develop innovative treatments. Sigma-1 receptor agonists, which are the focus of our research, may provide a novel therapeutic approach for the treatment of diseases associated with chronic tissue scarring.<\/p>\n

In our experiments conducted on various animal and in vitro<\/em> models, we use the most advanced molecular biology and imaging methods, which contribute to a deeper understanding of the biological processes underlying the pathomechanisms of diseases.<\/p>\n

Our team comprises five postdoctoral researchers, five PhD students, and several undergraduate students. Our work is supported by the prestigious Lend\u00fclet program, the National Research, Development, and Innovation Fund, and other significant grants.<\/p>\n","protected":false},"excerpt":{"rendered":"

Vezet\u0151: Prof. Dr. Fekete Andrea A t\u00f6bb mint k\u00e9t \u00e9vtizedes alapkutat\u00f3i \u00e9s klinikai farmakol\u00f3giai m\u00faltj\u00e1val rendelkez\u0151 MTA-SE Lend\u00fclet Diab\u00e9tesz Kutat\u00f3csoport els\u0151dleges c\u00e9lja, hogy laborat\u00f3riumi felfedez\u00e9seit klinikai gyakorlatba \u00fcltesse. Kutat\u00e1saink a cukorbetegs\u00e9g olyan sz\u00f6veti hegesed\u00e9ssel j\u00e1r\u00f3 sz\u00f6v\u0151dm\u00e9nyeire f\u00f3kusz\u00e1lnak, mint a diab\u00e9teszes vesebetegs\u00e9g, valamint a glauk\u00f3ma. A cukorbetegs\u00e9g t\u00f6bb mint 500 milli\u00f3 embert \u00e9rint vil\u00e1gszerte, a betegs\u00e9g …<\/p>\n","protected":false},"author":101740,"featured_media":0,"parent":15,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-200","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/users\/101740"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/comments?post=200"}],"version-history":[{"count":9,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/200\/revisions"}],"predecessor-version":[{"id":6328,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/200\/revisions\/6328"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/15"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/media?parent=200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/categories?post=200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/tags?post=200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}